[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Fudan University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":606},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,80,0,25,[9,47,79,103,124,151,170,189,212,237,268,294,316,348,373,391,415,435,454,476,496,517,539,562,583],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100633742","phase-3-statins-study-in-children-of-acute-kawasaki-disease-with-coronary-artery-abnormalities-100633742",false,"NCT07530640","Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities","Clinical Study of Atorvastatin in the Treatment of Acute Kawasaki Disease Complicated With Coronary Artery Abnormalities in Children","Inclusion Criteria:\n\n* KD complicated with CAA, less than 20 days after the onset of KD, or more than 20 days after onset but the KD inflammation has not been controled.\n* IVIG and\u002For other anti-inflammatory treatments have been used\u002Fare being used.\n* The guardians agree to atorvastatin treatment and sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients with history of family hypercholesterolemia\u002Ftaking statins\u002Fsevere chronic diseases.\n* Patients with abnormal laboratory data including CK≥500U\u002FL, total cholesterol\\\u003C3.1mmol\u002FL, ALT or AST≥ 2 times the upper limit of normal.\n* The guardians do not agree to atorvastatin treatment.","ALL","2 Years","18 Years",{"count":21,"type":22},9,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The goal of this observational study is to learn about the safety and effects of atorvastatin in treatment of Chinese Kawasaki disease (KD) children complicated with coronary artery abnormalities (CAA) in acute phase. The main questions it aims to answer are: Is atorvastatin safe in Chinese children of acute KD? Does atorvastatin contribute to control the acute inflammation in KD and improve the CAA?",[28,29],"Kawasaki Disease","Coronary Artery Abnormalities",[28,31,32,33],"Coronary artery abnormalities","Atorvastatin","Acute","RECRUITING","2026-06-14",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":38},"2026-06-08",{"date":42,"type":22},"2027-09-30",{"name":44,"class":45},"Children's Hospital of Fudan University","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100643082","clinical-study-of-traditional-chinese-medicine-in-the-treatment-of-phlegm-dampness-intrinsic-precocious-puberty-100643082","NCT07637019","Clinical Study of Traditional Chinese Medicine in the Treatment of Phlegm-dampness Intrinsic Precocious Puberty","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Sanghe Jianghuo Granules in the Treatment of Girls Aged 5-8.5 Years With Precocious Puberty and Phlegm-Dampness Internal Accumulation Syndrome According to Traditional Chinese Medicine","SHJG-PP","Inclusion Criteria:\n\n1. Female, aged between 5 and 9 years (inclusive).\n2. Presence of secondary sexual characteristics before 8 years of age, consistent with simple premature thelarche \u002F initial central precocious puberty (CPP) \u002F Tanner stage II.\n3. Traditional Chinese Medicine (TCM) syndrome differentiation: Phlegm-dampness internal accumulation syndrome.\n4. Body mass index (BMI) greater than the 50th percentile for same age and sex.\n5. Initial case, no prior medication for precocious puberty (including but not limited to GnRHa, sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines) within the last 3 months.\n6. Informed consent signed by the legal guardian(s), with ability to comply with the follow-up schedule.\n\nExclusion Criteria:\n\n1. Secondary precocious puberty due to central nervous system organic lesions, thyroid or adrenal disorders, ovarian tumors, or other underlying conditions.\n2. Severe hepatic or renal dysfunction, or hematological diseases.\n3. Use of sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines within the last 3 months.\n4. Inability to cooperate with examinations or poor compliance with follow-up visits (e.g., inability to complete ultrasound, blood collection, or scheduled visits).","FEMALE","5 Years","9 Years",{"count":59,"type":22},200,[61],"NA","Precocious puberty is characterized by the premature appearance of secondary sexual characteristics. Globally, the timing of puberty onset in children has shown a certain tendency to advance. In China, the incidence of precocious puberty has been increasing year by year. Precocious puberty exerts long-term and systemic impacts on children's health: advanced bone age leads to short stature; earlier sexual development than peers may induce emotional problems such as anxiety and inferiority; it may increase the risk of obesity and type 2 diabetes, posing long-term hazards to cardiovascular health; it may also result in irregular menstruation or dysmenorrhea, exerting indirect effects on reproductive health.\n\nModern traditional Chinese medicine (TCM) holds that: various factors lead to liver-kidney yin deficiency, hyperactivity of ministerial fire, and early arrival of tian gui (the substance responsible for promoting growth, development and reproduction), thereby triggering premature sexual development. The main syndrome types identified in clinical practice include yin deficiency with fire hyperactivity syndrome, liver stagnation transforming into fire syndrome, and phlegm-dampness internal accumulation syndrome.\n\nSince the late 1970s, the investigators' department has taken the lead in treating precocious puberty with TCM diagnostic methods, proposing that the pathogenesis of precocious puberty lies in \"kidney yin deficiency and hyperactivity of ministerial fire\", and adopting the therapy of nourishing yin and purging fire for its treatment. A number of studies have confirmed that TCM medicines with the effects of nourishing yin and purging fire can effectively alleviate the yin deficiency with fire hyperactivity syndrome in children, delay the development of secondary sexual characteristics and bone age.\n\nAt present, central precocious puberty is mostly treated with gonadotropin-releasing hormone analogs (GnRHa). However, this treatment has the drawback of inhibiting the growth axis, yielding limited benefits for children with advanced bone age, overweight or obesity, and may even affect glucose and lipid metabolism. Moreover, some children with precocious puberty complicated with obesity may be intolerant to this therapy. In contrast, TCM therapy and integrated TCM-Western medicine therapy can effectively delay the development of secondary sexual characteristics and advanced bone age, and improve final adult height, thus being widely applied in China.\n\nAlthough a large number of relevant studies have been reported in recent years and TCM diagnosis and treatment guidelines for precocious puberty have been formulated, there is still a lack of high-quality evidence-based medical research to support the advantageous aspects of integrated TCM-Western medicine diagnosis and treatment. Additionally, the underlying mechanisms of diagnosis and treatment for different syndrome types of precocious puberty remain insufficiently studied.\n\nIn this study, the investigators will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Sanghe Jianghuo Granules on the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, metabolic homeostasis and inflammatory microenvironment, so as to verify its efficacy and safety. Furthermore, combined with transcriptomics, proteomics and network pharmacology, the investigators will identify the key targets and action pathways of Sanghe Jianghuo Granules, and verify its regulatory effect on the HPG axis through in vivo and in vitro experiments.",[64],"Precocious Puberty",[64,66,67,68],"Sanghe Jianghuo Granules","Traditional Chinese Medicine","Phlegm-Dampness Syndrome","NOT_YET_RECRUITING","2026-06-04",{"date":72,"type":38},"2026-06-09",{"date":74,"type":22},"2026-07-01",{"date":76,"type":22},"2028-06-30",{"name":44,"class":45},5,{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":17,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":86,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100403182","child-parent-familial-hypercholesterolemia-screening-100403182","NCT04529967","Child-Parent Familial Hypercholesterolemia Screening","Child-Parent Screening of Familial Hypercholesterolemia in Children","Inclusion Criteria:\n\n* Receive routine child care\n* aged 1 - 3 years old ( date of investigate minus date of birth)\n\nExclusion Criteria:\n\n* It is up to the researcher to decide whether it is suitable to participate in this research","1 Year","3 Years",{"count":89,"type":22},15000,"OBSERVATIONAL","Child-parent screening for familial hypercholesterolemia has been proposed to identify children and their parent who are carrier of mutations and with high risk for inherited premature coronary artery disease. The investigators assessed the efficacy and feasibility of such screening in primary care practice.\n\nkey scientific questions:\n\n1. The 95th and 99th percentile of finger blood TC in children of 2 years old.\n2. Mutations that contribute to high TC status ( serum TC \\>99th percentiles) compared with international FH48 panel for FH genetic screening.",[93],"Familial Hypercholesterolemia","2026-05-13",{"date":96,"type":38},"2026-05-15",{"date":98,"type":38},"2025-04-01",{"date":100,"type":22},"2026-09-30",{"name":44,"class":45},6,{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":19,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":4},"100640538","feasibility-and-preliminary-efficacy-of-a-child-life-based-breathing-exercise-program-for-children-recovering-from-severe-pneumonia-a-pilot-randomized-controlled-trial-100640538","NCT07593989","Feasibility and Preliminary Efficacy of a Child Life-Based Breathing Exercise Program for Children Recovering From Severe Pneumonia: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n1. Children aged 6-18 years.\n2. Diagnosed with severe pneumonia and in the recovery phase.\n3. Written informed consent is obtained from caregivers, and assent is obtained from children when appropriate.\n\nExclusion Criteria:\n\n1. Contraindications to breathing exercise, including: (a) hemodynamic instability (e.g., bradycardia or tachycardia, arrhythmia, hypotension or hypertension); (b) open sternal incision; (c) extracorporeal membrane oxygenation (ECMO); (d) acute phase of severe wheezing or stridor; and (e) severe pulmonary hypertension.\n2. Communication disorders.","6 Years",{"count":111,"type":22},30,[61],"The goal of this pilot randomized controlled trial is to evaluate the feasibility and preliminary efficacy of a child life-based breathing exercise program for children recovering from severe pneumonia. The main questions it aims to answer are:\n\n* Is the child life-based breathing exercise program feasible for hospitalized children recovering from severe pneumonia?\n* Can the program improve caregiver satisfaction and promote recovery in children with severe pneumonia?\n\nResearchers will compare a child life-based breathing exercise program combined with routine health education with routine health education alone to determine whether the intervention improves rehabilitation outcomes.\n\nParticipants will:\n\n* Receive either routine health education alone or routine health education combined with the child life-based breathing exercise program\n* Participate in breathing exercise training during hospitalization\n* Complete assessments of caregiver satisfaction and clinical recovery outcomes, including improvement in chest imaging findings and time to resolution of symptoms such as cough, fever, and dyspnea.",[115],"Severe Pneumonia","2026-05-12",{"date":118,"type":38},"2026-05-18",{"date":120,"type":22},"2026-06-01",{"date":122,"type":22},"2027-06-01",{"name":44,"class":45},{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":23,"phases":136,"briefSummary":137,"conditions":138,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":145,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":46},"100601793","effectiveness-of-high-energy-density-enteral-nutrition-for-enhancing-physical-growth-and-cognitive-brain-development-in-infants-with-congenital-heart-disease-100601793","NCT07115108","Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease","Effectiveness of High-Energy Density Enteral Nutrition for Enhancing Physical Growth and Cognitive Brain Development in Infants With Congenital Heart Disease: A Randomized Controlled Study","RCT","Inclusion Criteria:\n\n* Diagnosed with congenital heart disease through symptoms, physical signs, imaging, and ultrasound examinations.\n* Age 0-6 months\n* Children with nutritional risks (defined by STRONGkids: Nutritional risk screening tool for children )\n* Artificial or mixed feeding\n* Open heart surgery under cardiopulmonary bypass\n* The guardians of the children voluntarily participate in this study and sign a written informed consent form before the surgery.\n\nExclusion Criteria:\n\n* Diagnosed with major non cardiac diseases leading to nutritional intake disorders, such as congenital gastrointestinal malformations, preoperative diagnosis of gastroesophageal reflux, genetic diseases related to growth restriction, and various syndromes with chromosomal abnormalities (trisomy 21 syndrome, trisomy 18 syndrome)\n* Abnormal immune system function due to congenital or acquired factors, unable to effectively resist pathogens or eliminate abnormal cells, which can be divided into primary and secondary immunodeficiencies.\n* Any pre - operative history of neurological diseases (e.g., encephalitis, epilepsy).\n* Secondary or primary gastrointestinal infection symptoms such as abdominal distension and diarrhea after surgery.\n* Estimated stay time in the postoperative intensive care unit ≤ 2 days","0 Months","6 Months",{"count":135,"type":22},160,[61],"The purpose of this study is to compare the effect of high and ordinary energy density enteral nutrition for improving physical growth and brain cognitive development in infants with congenital heart disease after operation, as well as evaluate the safety of interventions.",[139,140,141],"Congenital Heart Disease","Enteral Nutrition","Pediatrics",[143,144,141],"Congenital heart disease","Enteral nutrition",{"date":94,"type":38},{"date":147,"type":38},"2025-10-13",{"date":149,"type":22},"2026-12-31",{"name":44,"class":45},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":158,"maxAge":19,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":167,"leadSponsor":169,"locationsCount":46},"100592967","early-phase-1-cs-206-in-patients-with-sickle-cell-disease-100592967","NCT07000318","CS-206 in Patients With Sickle Cell Disease","An Open-Label Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous CD34+ Human Hematopoietic Stem Cells Modified Using Transformer Base Editor in Participants With Severe Sickle Cell Disease","Inclusion Criteria:\n\n* Participants must be between 12 to 18 years old (inclusive). Participants or their legal guardians (for participants below 18 years old) must provide written informed consent before any study-related procedures.\n* Participants must have a Documented βS\u002FβS, βS\u002Fβ0 or βS\u002Fβ+ genotype.\n* Participants must have at least one of the following conditions\n\n  1. At least 2 occurrences of any of the following events within 2 years prior to screening.\n\n     1. Acute pain crisis: requiring a visit to a medical facility and administration of pain medications (opioids or intravenous NSAIDs) or red blood cell transfusions.\n     2. Acute chest syndrome: defined by the presence of a new pulmonary infiltrate on a chest X-ray, associated with pneumonia-like symptoms, including chest pain, fever, or respiratory distress.\n     3. Priapism lasting more than 2 hours and necessitating a visit to a medical facility for intervention.\n     4. Stroke or transient ischemic attack (TIA): confirmed by imaging studies (e.g., MRI or CT scan), including silent stroke, and overt stroke leading to neurological deficits lasting \\>24 hours.\n  2. Presence of red cell alloimmunization (\\>2 antibodies) and the need for ongoing chronic transfusions.\n  3. Participants who have failed, not tolerated, refused the standard of care for Sickle Cell Disease (SCD), or are unable to access the standard of care due to the availability\n  4. Other situations deemed appropriate for hematopoietic stem cell transplantation according to the sickle cell anemia treatment guidelines, as determined by the investigator.\n* Laboratory Parameters:\n\n  1. Documented Hemoglobin S (HbS) level ≥30% of total hemoglobin (Hb) concentration prior to transfusion.\n  2. HbF at screening \\\u003C 20%\n* Participants must have a Karnofsky Performance Status (KPS for participants above 16 years old, inclusive) or Lansky Play-Performance Scale (LPPS for participants below 16 years old) score of ≥70, indicating sufficient functional status to undergo the intervention.\n* Willing to comply with the protocol requirements, use contraception as required, attend regular follow-up visits, and cooperate with examinations\n\nExclusion Criteria:\n\n* Female participants who are pregnant, breastfeeding, or planning pregnancy during the study period are excluded.\n* Participation in another investigational drug trial within 30 days prior to screening or within 5 half-lives (whichever is longer).\n* Subjects who have received or are receiving luspatercept treatment within 3 months prior to screening.\n* Subjects who have previously received any gene therapy for the disease.\n* Subjects with a fully matched related donor who are already scheduled for allogeneic hematopoietic stem cell transplantation.\n* More than 10 unplanned hospitalizations or emergency visits within 12 months prior to screening, which the investigator believes are related to significant chronic pain rather than acute pain crisis (VOC).\n* Severe liver dysfunction:\n\n  1. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\>3× the upper limit of normal (ULN) or:\n  2. International Normalized Ratio (INR) \\>1.5× ULN\n* Severe renal impairment (creatinine clearance \\\u003C30 mL\u002Fmin\u002F1.73 m²) are excluded.\n* Subjects with HIV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or Treponema pallidum infection during the screening period; those with active HBV or HCV infection; or known tuberculosis or parasitic infection, etc. Excludes subjects with stable hepatitis B (HBV-DNA negative) after treatment and those cured of hepatitis C (HCV-RNA negative). Known active bacterial, viral, or fungal infections.\n* Deemed unsuitable for autologous hematopoietic stem cell transplantation procedures as determined by the investigator.\n* Other situations deemed unsuitable for this study as determined by the investigator.","12 Years",{"count":78,"type":22},[161],"EARLY_PHASE1","The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-206 injection in treating sickle cell disease.",[164],"Sickle Cell Disease",{"date":96,"type":38},{"date":100,"type":22},{"date":168,"type":22},"2029-03-31",{"name":44,"class":45},{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":184,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":188,"locationsCount":46},"100580043","close-loop-smart-weaning-for-ino-with-pphn-100580043","NCT06832163","Close Loop Smart Weaning for INO With PPHN","Close Loop Smart Weaning Protocol for Inhaled Nitric Oxide Therapy With PPHN","Inclusion Criteria:\n\n1. The administration of inhaled nitric oxide (iNO) has commenced or is anticipated to commence for a duration of 24 hours or more, based on a clinical diagnosis of persistent pulmonary hypertension of the newborn (PPHN);\n2. There is a demonstrable positive response to iNO treatment;\n3. The iNO delivery system employed is appropriate and meets the conditional requirements, featuring an intelligent closed-loop offline functionality;\n4. The guardian or legal representative possesses a comprehensive understanding of the potential benefits and risks associated with participation in this study and has expressed a willingness to consent by signing the informed consent document.\n\nExclusion Criteria:\n\n1. There are established contraindications associated with the use of nitric oxide, which include the following conditions:\n\n   1. Severe hypoplasia of the left heart or duct-dependent congenital heart disease;\n   2. Life-threatening congenital anomalies and congestive heart failure;\n   3. Congenital methemoglobinemia;\n   4. Significant hemorrhagic events, such as intracranial hemorrhage, intraventricular hemorrhage, and pulmonary hemorrhage.\n2. Patients with chronic pulmonary conditions and other refractory diseases are not permitted to initiate withdrawal from the inhaled nitric oxide (iNO) treatment within a seven-day period following its administration.\n3. In cases where there is no observable response to iNO or if the duration of use is less than 30 minutes, a strict tapering protocol for withdrawal is not required.\n4. If the concentration of iNO treatment exceeds 20 parts per million (ppm) during the initiation phase or if the starting concentration for withdrawal is below 20 ppm, specific considerations must be taken into account.\n5. Participation in concurrent clinical trials involving other pharmacological agents or medical devices is prohibited.\n6. The investigator may determine that participation in this study is not appropriate for certain individuals.",{"count":111,"type":22},[61],"In contemporary clinical practice concerning the administration of inhaled nitric oxide (iNO) within neonatal intensive care units (NICUs), a stepwise reduction approach is frequently employed in accordance with established neonatal guidelines. Nonetheless, the comparative advantages of a linear reduction strategy-characterized by a gradual decrease in inhalation concentration-over the traditional stepwise method in terms of efficacy and safety have yet to be conclusively established. Furthermore, existing iNO delivery devices necessitate that healthcare professionals manually adjust parameters at intervals dictated by the patient's condition. This reliance on subjective clinical judgment often results in variability and a lack of standardization in the duration of the weaning process. Additionally, the protracted and intricate nature of the weaning procedure considerably heightens the workload for healthcare staff. Importantly, the development of a scientifically grounded, standardized, and real-time feedback mechanism for weaning may enhance clinical outcomes for patients and mitigate the risks associated with inappropriate weaning practices or inconsistent manual interventions. Consequently, this study seeks to leverage the newly introduced \"intelligent closed-loop weaning\" feature of the latest generation of iNO devices to facilitate automated linear concentration reduction during the weaning process. This innovation aims to alleviate the burden on healthcare personnel while establishing a more standardized and scientifically robust weaning protocol. However, it is noteworthy that there is currently a lack of clinical evidence, both domestically and internationally, regarding the safety and efficacy of this device's weaning protocol, underscoring the urgent need to validate its safety and effectiveness in real-world clinical settings.",[181,182],"Persistent Pulmonary Hypertension of the Newborn","Inhaled Nitric Oxide",[182,181],{"date":94,"type":38},{"date":186,"type":38},"2025-10-01",{"date":149,"type":22},{"name":44,"class":45},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":17,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":46},"100510351","preventive-effect-of-prophylactic-oral-antibiotics-against-cholangitis-after-kasai-portoenterostomy-100510351","NCT05925309","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients whose age of operation is 14-90 d. Sex and race are not restricted;\n* Patients who are born with gestational age older than 36 weeks;\n* Patients whose body weight before operation \\> 2 kg;\n* Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University;\n* The type-III BA diagnosis is based on cholangiography or operation;\n* Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported;\n* Patients who are not allergic to postoperative medications;\n* Patients who haven't accepted other antibiotic or probiotic therapy.\n\nExclusion Criteria:\n\n* Patients with cholestasis of non-BA disease;\n* Patients who have undergone KP at other institutions;\n* Patients whose pathohistological diagnosis is in doubt;\n* Patients who undergo liver transplantation immediately after KP;\n* Patients with other liver diseases or severe complications (e.g., severe pulmonary hypertension, renal failure, intracranial hemorrhage, etc.) requiring surgical intervention or other medical therapy;\n* Patients with severe cardiac, renal, or central nerve system malformations (e.g., tetralogy of Fallot, transposition of the great arteries, cerebral dysplasia, etc.) and have poor prognosis;\n* Patients judged by the researchers that they can not comply with the study requirements.","14 Days","90 Days",{"count":199,"type":22},356,[61],"This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.",[203,204,205],"Biliary Atresia","Cholangitis","Anti-Bacterial Agents",{"date":96,"type":38},{"date":208,"type":38},"2023-07-01",{"date":210,"type":22},"2029-12-31",{"name":44,"class":45},{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":219,"minAge":220,"maxAge":19,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":46},"100635647","phase-4-evaluating-the-safety-and-efficacy-of-decitabine-in-the-treatment-of-xmen-patients-100635647","NCT07555405","Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients","Single-arm Clinical Study Evaluating the Safety and Efficacy of Decitabine in the Treatment of X-linked MAGT1 Deficiency With Increased Susceptibility to EBV Infection and N-linked Glycosylation Defect (XMEN) Patients","Inclusion Criteria:\n\n1. Male participants aged 1 month to 18 years old.\n2. Confirmed MAGT1 gene mutation by genetic testing.\n3. Clinical manifestations consistent with XMEN disease, including liver dysfunction and\u002For EBV infection.\n4. Reduced lymphocyte NKG2D expression.\n5. Vital signs within normal range at screening.\n6. Expected survival ≥ 6 months.\n7. Able to comply with study procedures.\n8. Guardian and participant provide written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to decitabine or any excipient.\n2. Hematopoietic stem cell transplantation within 1 year before enrollment.\n3. Severe concurrent organ dysfunction or systemic disease.\n4. Positive HBsAg, anti-HCV, syphilis, or HIV test.\n5. Neurological or psychiatric disorders that impair compliance.\n6. Participation in another clinical trial within 3 months.\n7. Other conditions judged inappropriate by the investigator.","MALE","1 Month",{"count":102,"type":22},[223],"PHASE4","This is a single-arm, open-label, single-center, exploratory clinical trial evaluating the safety and efficacy of decitabine in male patients aged 1 month to 18 years with X-linked magnesium transporter 1 (MAGT1) deficiency. Eligible patients have a confirmed MAGT1 gene mutation leading to XMEN disease ( X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect). The study will assess changes in liver function, immune function, and NKG2D expression, as well as adverse events, over four treatment cycles and the follow-up period.",[226],"MAGT1 Deficiency",[228],"Decitabine","2026-04-24",{"date":231,"type":38},"2026-04-29",{"date":233,"type":22},"2026-04",{"date":235,"type":22},"2028-12",{"name":44,"class":45},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":244,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":252,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":267,"locationsCount":46},"100634385","optimizing-early-nutrition-management-of-extremely-andor-very-preterm-infants-100634385","NCT07538999","Optimizing Early Nutrition Management of Extremely and\u002For Very Preterm Infants","Optimizing Early Nutrition Management of Extremely and\u002For Very Preterm Infants Based on Best Clinical Practice: a Real Word Study","Inclusion Criteria for intervention group:\n\n* (1) Admitted to the Neonatal Department of Children's Hospital of Fudan University during the study period.\n* (2) Preterm infants with a gestational age \\\u003C 32 weeks or a birth weight \\\u003C 1500 g.\n* (3) Admitted to the study center within 24 hours after birth.\n* (4) Obtained informed consent from family members. Exclusion Criteria for intervention group\n* (1) Newborns with severe congenital diseases, severe congenital malformations, chromosomal abnormalities, or genetic metabolic diseases.\n* (2) Death or discharge within two weeks after birth.\n\nInclusion Criteria for control group:\n\n* (1) Admitted to the Neonatal Department of Children's Hospital of Fudan University from January 2025 to December 2025.\n* (2) Preterm infants with a gestational age \\\u003C 32 weeks or a birth weight \\\u003C 1500 g.\n* (3) Admitted to the study center within 24 hours after birth. Exclusion Criteria for control group\n* (1) Newborns with severe congenital diseases, severe congenital malformations, chromosomal abnormalities, or genetic metabolic diseases.\n* (2) Death or discharge within two weeks after birth.","1 Day",{"count":59,"type":22},[61],"A clinical quality improvement bundle on early nutrition supplementation is developed to improving the clinical outcomes (including growth, organ function, and neurodevelopment outcomes) of extremely and\u002For very preterm infants. This bundle consists of three aspects: individualized and precise human milk feeding, early enteral zinc supplementation, and routine parenteral carnitine supplementation.",[249,250,251],"Nutrition Intervention","Quality Improvement","Preterm Infant",[253,254,255,256,257,258,259,260],"preterm infants","nutrition","bundle","zinc supplementation","carnitine supplementation","growth","outcomes","human milk feeding","2026-04-13",{"date":263,"type":38},"2026-04-20",{"date":265,"type":22},"2026-04-01",{"date":210,"type":22},{"name":44,"class":45},{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":275,"enrollmentInfo":276,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":278,"conditions":279,"keywords":283,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":46},"100444837","high-medium-chain-triglyceride-nutritional-support-in-infants-with-biliary-atresia-100444837","NCT05072626","High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia","Study on High Medium-chain Triglyceride Nutritional Support in Infants With Biliary Atresia After Kasai Portoenterostomy","Inclusion Criteria:\n\nThe Kasai procedure for infants with biliary atresia under the age of 3 months.\n\nExclusion Criteria:\n\n* Complicated with cirrhosis, hepatitis, or other hepatic disorders;\n* Complicated with other systemic serious diseases (such as congenital multiple malformations, chromosome abnormalities)","3 Months",{"count":277,"type":22},300,"This study is a prospective, single center and observational open clinical study.",[203,280,281,282],"Infant","Nutrition Support","Medium-chain Triglyceride",[203,284,281,285],"Kasai portoenterostomy","medium-chain triglyceride","2026-03-30",{"date":288,"type":38},"2026-04-03",{"date":290,"type":38},"2021-10-11",{"date":292,"type":22},"2028-12-31",{"name":44,"class":45},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":133,"enrollmentInfo":301,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":46},"100416804","enteral-nutrition-in-infants-with-ileostomy-100416804","NCT04707443","Enteral Nutrition in Infants With Ileostomy","Correlation Between Enteral Nutrition and Early Prognosis in Infants Aged Under 6 Months Following Enterostomy","Inclusion Criteria:\n\n* After birth, infants aged 0-6 months (including neonates) undergo small bowel ostomy for various reasons.\n\nExclusion Criteria:\n\n* Primary liver and kidney dysfunction, congenital multiple malformations and chromosomal abnormalities.",{"count":302,"type":22},110,"This study is a prospective, single center, practical, and observational open clinical study.",[305],"Nutrition of Ileostomy Infants",[307,308,144,309,310],"ileostomy","Human breast milk","extensive hydrolyzed formula","amino acid formula",{"date":288,"type":38},{"date":313,"type":38},"2021-07-08",{"date":292,"type":22},{"name":44,"class":45},{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":17,"minAge":220,"maxAge":19,"enrollmentInfo":323,"targetDuration":87,"studyType":90,"phases":4,"briefSummary":325,"conditions":326,"keywords":336,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":46},"100567463","magnetoencephalography-in-children-100567463","NCT06668519","Magnetoencephalography in Children","An Observational Study on the Clinical Application of Magnetoencephalography in Children With Neurodevelopmental Disorders","Inclusion Criteria:\n\n1. aged 1 month-18 years old (date of investigate minus date of birth)\n2. epilepsy\n3. intracranial tumors\n4. cerebrovascular diseases\n5. autism\n6. mental retardation\n7. ADHD\n8. tic disorder\n9. neuropsychiatric disorders\n\nExclusion Criteria:\n\n1.Unable to cooperate with the exam of MEG",{"count":324,"type":22},1500,"This study is a single-center observational clinical study, which evaluates the diagnostic value of magnetoencephalography (MEG) in the diagnosis of neurodevelopmental diseases in children, such as the localization of epileptic foci and brain functional areas, intracranial tumors, cerebrovascular diseases, autism, mental retardation, and neuropsychiatric disorders.",[327,328,329,330,331,332,333,334,335],"Epilepsy","Intracranial Tumors","Cerebrovascular Disease","Autism","ADHD - Attention Deficit Disorder With Hyperactivity","Neuropsychiatric Disorders","Tic Disorder, Childhood","Mental Retardation","Developmental Disabilities",[337,338,339],"neurodevelopmental diseases","magnetoencephalography","pediatric","2026-03-24",{"date":342,"type":38},"2026-03-25",{"date":344,"type":38},"2024-09-25",{"date":346,"type":22},"2027-12-30",{"name":44,"class":45},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":354,"sex":17,"minAge":4,"maxAge":109,"enrollmentInfo":355,"targetDuration":4,"studyType":23,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":372},"100517537","urine-and-ultrasound-screening-for-kidney-disease-in-children-100517537","NCT06018831","Urine and Ultrasound Screening for Kidney Disease in Children","Inclusion Criteria:\n\n* All consecutive live newborn infants(regardless of physical condition)\n* Complete at least 3 years of follow-up\n\nExclusion Criteria:\n\n* Declining the screening\n* Missing",true,{"count":356,"type":22},13000,[61],"The aim of this study is to early detect kidney disease in the natural population cohort of children by urine and ultrasound screening, to assist in the precise prevention and treatment of children's kidney disease, and to establish a risk prediction system for children's kidney disease. About 10,000 children called KunQi Cohort are born in Jiangsu Province(8,000 in Kunshan and 2,000 in Qidong) and about 3,000 born in Shanghai. Through the project, child who is found with abnormal urine or ultrasound result will be referred to Children's Hospital of Fudan University to get further examination and treatment.",[360,361,362,363,364],"Kidney Diseases","Diagnostic Techniques","Ultrasound","Urinalysis","Child, Only",{"date":366,"type":38},"2026-03-27",{"date":368,"type":38},"2022-04-12",{"date":370,"type":22},"2028-02",{"name":44,"class":45},2,{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":377,"acronym":4,"eligibilityCriteria":378,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":380,"conditions":381,"keywords":383,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":46},"100504438","preoperative-serum-fgf19-in-the-prognosis-of-biliary-atresia-100504438","NCT05848310","Preoperative Serum FGF19 in the Prognosis of Biliary Atresia","Inclusion Criteria:\n\n* Samples diagnosed as biliary atresia in Children's Hospital of Fudan University\n* Samples with one-year follow-up records after surgery\n* Samples with a record of serum total bilirubin levels three months after surgery\n* Samples with preoperative serum left（volume \\> 500ul)\n\nExclusion Criteria:\n\n* None",{"count":59,"type":22},"To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia.",[203,382],"Prognosis",[203,384],"FGF19",{"date":366,"type":38},{"date":387,"type":38},"2023-10-15",{"date":389,"type":22},"2027-08",{"name":44,"class":45},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":87,"maxAge":398,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":405,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":46},"100500080","the-intervention-of-obesity-in-children-with-prader-willi-syndrome-using-prebiotics-and-probiotics-100500080","NCT05791604","The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics","The Safety and Effectiveness Study of Prebiotics and Probiotics in the Intervention of Obesity in Children With Prader-Willi Syndrome","Inclusion Criteria:\n\n* Pre-adolescent children with Prader Willi syndrome which were definitely diagnosed by gene testing.\n* Consistent with the diagnostic criteria for obesity.\n* Not participate in other research projects at present or three months before the research;\n* Agree to participate in the test and obtain the consent of their parents; voluntarily be the subjects and sign the informed consent form.\n\nExclusion Criteria:\n\n* Losing weight in ways other than the intervention measures of this project, such as taking weight loss drugs or known drugs that cause weight change;\n* Use antibiotics within 1 month before the study and lasted for 3 days or more;\n* Use probiotics within 1 month before the study and lasted for 3 days or more;\n* Complicated with liver and renal insufficiency (alanine aminotransferase and serum creatinine indexes exceed 2 times the upper limit of the normal value set by the hospital);\n* Have gastrointestinal diseases affecting food digestion and absorption (such as severe diarrhea, constipation, severe gastrointestinal inflammation, active gastrointestinal ulcer, acute cholecystitis, etc.); severe diarrhea refers to watery stool 3 or more times a day and lasts for 3 or more days. severe constipation refers to defecation 2 or less times a week with difficulty in defecation;\n* Surgery was performed within 1 year before the study (except for appendicitis and hernia surgery);\n* Have hepatitis B, active tuberculosis, AIDS and other infectious diseases;\n* Those who are suffering from mental illness and are taking psychotropic drugs such as antidepressants.","10 Years",{"count":400,"type":22},60,[61],"Prader-Willi syndrome (PWS) is a rare genetic disease, with hyperappetite and severe obesity. At present, there is no effective drugs and interventions to help control the appetite of PWS patients. More and more evidence has shown that gut microbiota is closely related to obesity. Probiotics and prebiotics can improve the structure of gut microbiota, thus improve blood lipid levels and other biochemical indicators of obese people. Therefore, this study intends to explore the effectiveness and safety of probiotics and prebiotics in controlling appetite and weight gain of PWS children.",[404],"Prader-Willi Syndrome",[406,407,408],"Prader-Willi syndrome","Probiotics","Prebiotics",{"date":366,"type":38},{"date":411,"type":38},"2023-04-01",{"date":413,"type":22},"2026-07-31",{"name":44,"class":45},{"id":416,"slug":417,"hasResults":12,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":109,"enrollmentInfo":422,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":434,"locationsCount":46},"100403054","whole-genome-sequencing-versus-whole-exome-sequencing-for-congenital-diarrhea-and-enteropahty-100403054","NCT04528303","Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty","A Randomized, Controlled Trial of the Effectiveness of Whole Genome Sequencing Versus Whole Exome Sequencing for Screening Patients With Congenital Diarrhea and Enteropathy (CODESeq)","Inclusion Criteria:\n\n* Patients with chronic diarrhea lasting greater than 2 months\n* Patients with consent from parents or legal guardians\n* Biological relative of a patient enrolled in this study.\n\nExclusion Criteria:\n\n* Chronic diarrhea caused by specific infections, i.e. CMV, Clostridioides difficile\n* Chronic diarrhea with necrotizing enterocolitis, short bowel syndrome\n* Functional diarrhea\n* Patients with previously confirmed monogenic diarrhea\n* Patients with poor compliance",{"count":423,"type":22},180,[61],"This study will seek to determine if whole genome sequencing (WGS) improves diagnostic rates, and outcomes for congenital diarrhea and enteropathy (CODE) patients. The investigator will enroll 180 patients in a randomized controlled study to either WGS or whole exome sequencing (WES). This study is designed to evaluate whether CODE patients would benefit from WGS guided precision medicine.",[427,428],"Diarrhea, Infantile","Enteropathy","2026-03-20",{"date":340,"type":38},{"date":432,"type":38},"2024-05-01",{"date":149,"type":22},{"name":44,"class":45},{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":439,"acronym":4,"eligibilityCriteria":440,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":441,"targetDuration":4,"studyType":23,"phases":443,"briefSummary":62,"conditions":444,"keywords":446,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":452,"leadSponsor":453,"locationsCount":46},"100617998","early-phase-1-research-of-integrated-traditional-chinese-and-western-medicine-on-precocious-puberty-100617998","NCT07325903","Research of Integrated Traditional Chinese and Western Medicine on Precocious Puberty","Inclusion Criteria:\n\n* pediatric patients clinically diagnosed with precocious puberty: girls who exhibit secondary sexual characteristics or gonadal development before the age of 8, accompanied by obesity (BMI ≥ P85), and classified as having a syndrome of yin deficiency with hyperactivity of fire complicated by phlegm-dampness. Inclusion age: girls aged 5 years to 9 years, all of whom are initial cases and have not received any drug treatment related to precocious puberty.\n\nExclusion Criteria:\n\n* Secondary precocious puberty, associated with diabetes, thyroid dysfunction, other endocrine disorders, and severe underlying conditions.",{"count":442,"type":22},100,[161],[445],"Puberty, Precocious",[447,66,130],"precocious puberty","2026-03-17",{"date":450,"type":38},"2026-03-19",{"date":265,"type":22},{"date":292,"type":22},{"name":44,"class":45},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":19,"enrollmentInfo":461,"targetDuration":4,"studyType":23,"phases":463,"briefSummary":464,"conditions":465,"keywords":467,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":471,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":475,"locationsCount":46},"100504374","effects-of-auricular-acupressure-versus-intermittent-dietary-restriction-in-children-with-gastric-heat-and-dampness-obstruction-100504374","NCT05847478","Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction","Effects of Auricular Acupressure Versus Intermittent Dietary Restriction in Children With Gastric Heat and Dampness Obstruction: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Have at least one of the following cardiometabolic risk factors: overweight or obesity, prediabetes, dyslipidemia or elevated blood pressure.\n* Traditional Chinese medical syndrome type is gastric heat and dampness obstruction syndrome.\n\nExclusion Criteria:\n\n* Diagnosis of obesity associated with genetic or endocrine diseases, including hypercortisolism, polycystic ovary syndrome, primary hypothyroidism and hypothalamic obesity.\n* Participating in other clinical trials or have participated in other clinical trials in recent 3 months.\n* Diagnosis of organic diseases, including heart, liver, kidney and brain or infectious diseases and mental diseases.",{"count":462,"type":22},240,[61],"This is a three-month randomized controlled trial to investigate the effects of auricular acupressure versus Intermittent carbohydrate restriction on cardiometabolic risk in obese children with gastric heat and dampness obstruction.",[466],"Obesity, Childhood",[468,469,470],"Auricular acupressure","Intermittent dietary restriction","Gastric Heat and Dampness Obstruction",{"date":450,"type":38},{"date":473,"type":38},"2023-06-07",{"date":149,"type":22},{"name":44,"class":45},{"id":477,"slug":478,"hasResults":12,"nctId":479,"briefTitle":480,"officialTitle":481,"acronym":482,"eligibilityCriteria":483,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":484,"targetDuration":4,"studyType":23,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":491,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":495,"locationsCount":46},"100462809","nurse-initiated-conversations-for-early-integration-of-palliative-care-in-pediatric-oncology-100462809","NCT05306509","Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology","Facilitating Early Integration of Palliative Care in Pediatric Oncology: Development and Implementation of a Nurse-initiated Conversation Program for Pediatric Cancer Patients and Their Families","NiCE","Inclusion Criteria:\n\n* Children within eight weeks of initial oncologic diagnosis or within eight weeks of relapse\u002Frecurrent disease diagnosis\n* Children speaking Chinese\n* Children's family caregivers accompanying the child in the hospital (only one family member is eligible to take this role under current hospital policy)\n* Children's family caregivers speaking Chinese\n* Health care providers who are taking care of the eligible children, including but not limited to physicians, nurses, and social workers\n\nExclusion Criteria:\n\n\\- Children who, in the opinion of their physician, are not capable mentally or verbally of participating in the survey or interview",{"count":485,"type":22},120,[61],"This study aims to develop and implement a pediatric palliative care (PPC) program. It is an open-label, randomized trial (2:1 randomization) in pediatric oncology department of Children's Hospital of Fudan University. The intervention group will receive Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NiCE). The control group will receive routine PPC (will be scheduled to meet with the PPC team only when participants themselves, their families, or the attending oncologist requested an appointment). The intervention will take 6 months.",[489,490],"Solid Tumor","Hematological Malignancies",{"date":450,"type":38},{"date":493,"type":38},"2022-08-01",{"date":413,"type":22},{"name":44,"class":45},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":19,"enrollmentInfo":503,"targetDuration":4,"studyType":23,"phases":505,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":516,"locationsCount":46},"100442629","phase-4-combined-immunosuppression-for-pediatric-crohns-disease-100442629","NCT05043870","Combined Immunosuppression for Pediatric Crohn's Disease","Combination Therapy of Infliximab and Immunosuppressives for Pediatric Crohn's Disease","Inclusion Criteria:\n\n1. 6-18 years old\n2. diagnosis of Crohn's Disease\n3. Pediatric Crohn's disease Activity Index (PCDAI)\\>30 or The Simple Endoscopic Score for Crohn Disease (SES-CD) \\>10 before treatment\n4. receiving exclusive enteral nutrition or corticosteroids as first-line treatment, Pediatric Crohn's disease Activity Index (PCDAI)\\>10 or The Simple Endoscopic Score for Crohn Disease (SES-CD)≥3 after exclusive enteral nutrition or corticosteroids\n5. The patient or legal guardian sign the informed consent documents\n\nExclusion Criteria:\n\n1. history of biological agents targeting at tumor necrosis factor (TNF)\n2. Crohn's Disease-related surgery\n3. infections\n4. tumors",{"count":504,"type":22},128,[223],"This is a randomized controlled trial to compare the efficacy and safety of infliximab and immunosuppressives therapy alone or in combination for pediatric Crohn's disease.",[508,509,510,511],"Crohn Disease","Infliximab","Immunosuppression","Children, Only",{"date":450,"type":38},{"date":514,"type":38},"2022-10-10",{"date":149,"type":22},{"name":44,"class":45},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":522,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":109,"maxAge":158,"enrollmentInfo":524,"targetDuration":4,"studyType":23,"phases":525,"briefSummary":526,"conditions":527,"keywords":529,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":46},"100531355","intervention-for-children-with-type-1-diabetes-targeting-gut-microbes-100531355","NCT06198725","Intervention for Children With Type 1 Diabetes Targeting Gut Microbes","TRIM1","Inclusion Criteria:\n\n* Diagnosed as type 1 diabetes for the first time according to the diagnostic criteria of the American diabetes Association (ADA) in the past 6 months;\n* One or more antibodies against GAD65, IAA, IA-2, ICA, and ZNT8 are positive;\n* The daily total dose of insulin per unit weight was less than 0.5 IU\u002Fkg\u002Fday three days prior to screening;\n* Fasting C-peptide (FCP)\\>0.1 nmol\u002FL (0.3ng\u002FmL);\n* Age range from 6 to 12 years old;\n* Have not participated in any other research projects at present;\n* The guardian signs the informed consent form, the child agrees to the study, and the child over 8 years old signs the informed consent form.\n\nExclusion Criteria:\n\n* Suffering from serious chronic and systemic diseases: tumors, immunodeficiency, heart failure, Cushing's syndrome, kidney diseases (including nephrotic syndrome, nephritis, glomerulonephritis, kidney stones, etc.), liver diseases (including autoimmune hepatitis, metabolic liver disease, non-alcoholic fatty liver disease, primary sclerosing cholangitis, chronic, persistent hepatitis, etc.), gallbladder diseases (including cholecystitis, gallstones, etc.), etc;\n* Suffering from acute or chronic gastrointestinal diseases such as Crohn's disease, ulcerative colitis, gastroesophageal reflux disease, gastrointestinal ulcers, celiac disease, or having defecation three or more times a day in the past week or more, accompanied by watery stools;\n* Blood pressure ≥ 95th percentile of the same gender, age, and height reference;\n* Plasma triglycerides of 9 years and below should be ≥ 1.12mmol\u002FL, and triglycerides of 10 years and above should be ≥ 1.46mmol\u002FL;\n* Used antibiotics within the past month for 3 days or more;\n* Currently suffering from infectious diseases;\n* Have the history of gastrointestinal surgery, surgery to remove appendicitis and hernia;\n* Evidence of pituitary dysfunction;\n* Use drugs other than insulin that can affect blood sugar levels;\n* Chromosomal abnormalities (such as trisomy 21 syndrome, Turner syndrome, etc.);\n* Have taken probiotics and probiotic products continuously for more than 3 days within the first month before enrollment;\n* Unable to guarantee sufficient time to participate in this project.",{"count":302,"type":22},[61],"The goal of this clinical study is to evaluate the effect of nutritional intervention program based on dietary products in the clinical treatment of newly diagnosed children with type 1 diabetes. The main question aims to answer is: whether high fiber diet can protect beta-cell function in children with newly onset type 1 diabetes.\n\nParticipants will take 12 weeks of high fiber diet intervention and beta-cell function and gut microbiota structure will be analyzed.",[528],"Type 1 Diabetes",[528,530,531,532],"High Fiber Diet","Beta-cell function","Gut microbiota","2026-03-15",{"date":448,"type":38},{"date":536,"type":38},"2024-01-08",{"date":149,"type":22},{"name":44,"class":45},{"id":540,"slug":541,"hasResults":12,"nctId":542,"briefTitle":543,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":546,"targetDuration":4,"studyType":23,"phases":548,"briefSummary":549,"conditions":550,"keywords":553,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":556,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":46},"100349861","sequential-transplantation-of-ucbscs-and-islet-cells-in-children-and-adolescents-with-monogenic-immunodeficiency-t1dm-100349861","NCT03835312","Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM","Sequential Transplantation of Umbilical Cord Blood Stem Cells and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency Type 1 Diabetes Mellitus","Inclusion Criteria:\n\n1.Type 1 diabetes mellitus children with genetic immunodeficiency\n\n1. Meet the diagnostic criteria of type 1 diabetes mellitus: clinical manifestations of typical diabetes mellitus include polyphagia, polyuria, weight loss, or diabetic ketoacidosis, confirmed by blood sugar level, islet function and autoimmune antibody.\n2. Existence of extrapancreatic organ damage: (1) inflammatory bowel disease, (2) impairment of renal function, (3) repeated infection of mouth, skin, anus or whole body, (4) immune hepatitis, (5) persistent chronic immune iridocyclitis, (6) immune adrenalinitis leading to adrenocortical dysfunction, (7) pituitary inflammation leading to hypophysis, (8) rheumatoid disease, (9) immune vasculitis, (10) systemic lupus erythematosus, (11) other organs besides thyroid function damage. Suffering from one or more of above diseases. Recurrence after receiving regular clinical treatment, including symptomatic treatment of organ protective drugs.\n3. Gene mutation was found according to gene diagnosis: gene mutation was found by gene sequencing. Literature searches at home and abroad confirmed that the defect of the gene resulted in autoimmune or immune dysfunction, resulting in multiple organ dysfunction and poor prognosis.\n\nExclusion Criteria:\n\n1. Mature and effective treatment methods are available.\n2. HIV, HBV and HCV were positive.\n3. A the active period of infection.\n4. At the active stage of malignant tumors.\n5. Combination of other fatal diseases.\n6. Existence of mental and psychological diseases.",{"count":547,"type":22},50,[61],"This study evaluates the efficacy of sequential transplantation of umbilical cord blood stem cells and islet cells in children with monogenic immunodeficiency type 1 diabetes mellitus. Umbilical cord blood stem cell transplantation will be performed first. Children with stable immune reconstruction will than receive islet cell transplantation.",[551,552],"Diabetes Mellitus, Type 1","Immunologic Deficiency Syndromes",[554,555],"Islets of Langerhans Transplantation","Cord Blood Stem Cell Transplantation",{"date":448,"type":38},{"date":558,"type":38},"2019-02-20",{"date":560,"type":22},"2030-12-31",{"name":44,"class":45},{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":569,"targetDuration":4,"studyType":23,"phases":571,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":580,"completionDateStruct":581,"leadSponsor":582,"locationsCount":46},"100572202","standardized-nutritional-management-of-pediatric-patients-with-solid-tumors-100572202","NCT06730204","Standardized Nutritional Management of Pediatric Patients With Solid Tumors","Nutrition Strategies and Malnutrition Assessment Management Systems for Preventing Malnutrition in Children With Solid Tumors: an Exploratory Intervention Study","1. Male and female, age 0-18 years old\n2. Pathological diagnosis is malignant solid tumor with untreated initial onset",{"count":570,"type":22},400,[61],"The purpose of this study is to establish a standardized nutrition intervention procedure for children with solid tumors, and to explore the effectiveness and clinical applicability of standardized nutrition management and short peptide-based enteral nutrition intervention for improving the nutritional status of children with malignant solid tumors.\n\nAfter admission, patients in the intervention group will receive standardized nutrition management provided by a nutrition support team composed of dietitians, nutritionists, clinicians, and nursing teams. Basic information, including diet, enteral and parenteral nutrition, nutritional status and clinical data, will be collected during the study.",[574,575,576],"Tumor, Solid","Children","Nutritional Intervention","2026-03-13",{"date":579,"type":38},"2026-03-16",{"date":208,"type":38},{"date":149,"type":22},{"name":44,"class":45},{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":590,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":594,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":605,"locationsCount":372},"100555706","effect-of-developmental-care-on-very-low-birth-weight-infants-100555706","NCT06515574","Effect of Developmental Care on Very Low Birth Weight Infants","Effect of Developmental Care on Very Low Birth Weight Infants: a Stepped-wedge Cluster Randomised Trial","Inclusion Criteria\n\n1. Birth weights less than 1500 g\n2. Admitted or transported to a level III NICU within 24h of birth\n3. OI\\>30\n\nExclusion Criteria:\n\n1. Severe congenital malformations\n2. various chromosomal disorders\n3. genetic metabolic diseases,\n4. severe neurological disorders","0 Days","30 Days",{"count":593,"type":22},1600,[61],"The goal of this clinical trial is to learn if developmental care works when implemented in very low birth weight infants. The main questions it aims to answer are:\n\n* Does developmental care shorten the length of hospital stay in the very low birth weight infants?\n* Does developmental care increase the opportunity of family centered care in the very low birth weight infants? The clinical trial will use a 36-month stepped-wedge cluster-randomised trial conducted across 40 Neonatal intensive care units . A developmental care bundle will be tailored to meet the identified needs of participating NICUs.",[597],"Intervention",[599],"developmental care",{"date":579,"type":38},{"date":602,"type":38},"2024-08-30",{"date":604,"type":22},"2027-12-01",{"name":44,"class":45},""]